Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-ABY-271 in HER2-positive Metastatic Breast Cancer
NCT07081555Phase 1Recruiting
- Sponsor
- Affibody Medical AB
- Start
- Oct 2025
- Primary completion
- Jan 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of [177Lu]Lu-ABY-271 in HER2-positive metastatic breast cancer (4 arms), sponsored by Affibody Medical AB. Primary endpoints: Treatment emergent adverse events at 43 days and Dose Limiting Toxicities at 43 days. Started Oct 2025; status: recruiting.
02
Drugs
[177Lu]Lu-ABY-271
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT07081555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07081555.